Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Carsten BrunnPresident and CEO | Cartesian TherapeuticsRNAC | Open-market sale | 01/06 | 01/08 | 23,766 sh | $6.82 | $162,084.12 | −6.8% |
Blaine DavisCFO | Cartesian TherapeuticsRNAC | Open-market sale | 01/06 | 01/08 | 10,591 sh | $6.82 | $72,230.62 | −8.0% |
Milos MiljkovicChief Medical Officer | Cartesian TherapeuticsRNAC | Open-market sale | 01/06 | 01/08 | 3,573 sh | $6.82 | $24,367.86 | −5.7% |
Timothy C. BarabeDirector | Cartesian TherapeuticsRNAC | Open-market buy | 25/12/04 | 25/12/08 | 30,000 sh | $6.86 | $205,800 | +123.1% |
Cartesian TherapeuticsRNAC | Open-market buy | 25/04/09–25/04/11 | 25/04/11 | 149,075 sh10 trades | $10.21avg. | $1,522,330.33 | No record | |
Cartesian TherapeuticsRNAC | Open-market buy | 25/03/18–25/03/20 | 25/03/20 | 89,863 sh3 trades | $15.26avg. | $1,371,173.29 | +1.1% | |
Cartesian TherapeuticsRNAC | Open-market buy | 25/01/13–25/01/14 | 25/01/15 | 20,967 sh3 trades | $17.47avg. | $366,353.06 | +0.2% | |
Cartesian TherapeuticsRNAC | Open-market sale | 25/01/03–25/01/06 | 25/01/07 | 17,271 sh2 trades | $16.78avg. | $289,729 | −7.8% | |
Cartesian TherapeuticsRNAC | Open-market sale | 25/01/03–25/01/06 | 25/01/07 | 7,989 sh2 trades | $16.78avg. | $134,019.16 | −7.8% | |
Cartesian TherapeuticsRNAC | Open-market sale | 25/01/03–25/01/06 | 25/01/07 | 2,550 sh2 trades | $16.78avg. | $42,777.46 | −4.6% | |
Cartesian TherapeuticsRNAC | Open-market sale | 25/01/03–25/01/06 | 25/01/07 | 1,880 sh2 trades | $16.78avg. | $31,537.88 | −5.0% | |
Cartesian TherapeuticsRNAC | Open-market sale | 25/01/03–25/01/06 | 25/01/07 | 4,875 sh2 trades | $16.78avg. | $81,780.38 | −7.3% | |
Cartesian TherapeuticsRNAC | Open-market sale | 25/01/03–25/01/06 | 25/01/07 | 1,797 sh2 trades | $16.78avg. | $30,145.5 | −4.3% | |
Cartesian TherapeuticsRNAC | Open-market buy | 24/12/19–24/12/23 | 24/12/23 | 52,189 sh5 trades | $18.49avg. | $965,005 | +0.6% | |
Cartesian TherapeuticsRNAC | Open-market sale | 24/12/09–24/12/10 | 24/12/11 | 13,664 sh3 trades | $25.26avg. | $345,099.96 | −21.1% | |
Cartesian TherapeuticsRNAC | Open-market sale | 24/11/19–24/11/21 | 24/11/21 | 38,689 sh4 trades | $16.78avg. | $649,069.63 | −43.1% | |
Cartesian TherapeuticsRNAC | Open-market buy | 24/11/14–24/11/18 | 24/11/18 | 431,940 sh5 trades | $17.07avg. | $7,372,444.17 | +5.4% | |
Cartesian TherapeuticsRNAC | Open-market sale | 24/11/14–24/11/18 | 24/11/18 | 82,368 sh5 trades | $17.46avg. | $1,438,086.52 | −61.7% | |
Cartesian TherapeuticsRNAC | Open-market sale | 24/11/14–24/11/15 | 24/11/18 | 52,115 sh3 trades | $16.79avg. | $875,025.9 | −66.8% | |
Cartesian TherapeuticsRNAC | Open-market sale | 24/11/14–24/11/15 | 24/11/18 | 55,000 sh2 trades | $16.50avg. | $907,350 | −75.1% |